News ICER says AZ's new hypertension drug too expensive ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.
News Novo Nordisk fight with KBP Bio will go to arbitration Singapore court keeps an asset freeze on KBP Bio, saying the merits of its dispute with Novo Nordisk over a licensing deal must go to arbitration.
News AZ gets first okay for new hypertension drug baxdrostat AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.
News AZ uses a priority review voucher for baxdrostat filing Seeking a lead over rival Mineralys, AstraZeneca is using a priority review voucher for its US filing for uncontrolled hypertension drug baxdrostat.
News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News AHA: Cash for drug adherence study has disappointing result People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.